Physician profile
Silpa Avula
NPI 1386675981
$2,530.15
in general payments reported to CMS, 2019-2025
19 companies · $414 in 2025
The $414 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $378 · 2020: $142 · 2021: $359 · 2022: $242 · 2023: $594 · 2024: $401 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,408.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $439.90 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $287.21 | 2019-2023 | Brilinta, Farxiga |
| Pfizer INC. | $251.00 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.48 | 2019 | |
| Merck Sharp & Dohme LLC | $202.64 | 2021-2023 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $173.61 | 2022-2025 | Eliquis |
| Boston Scientific Corporation | $162.86 | 2022-2025 | Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $121.24 | 2021-2025 | |
| Amgen INC. | $109.86 | 2021-2025 | Repatha, Repatha |
| Bardy Diagnostics, INC. | $107.37 | 2020-2021 | |
| Novo Nordisk INC | $107.33 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $80.03 | 2019-2024 | Mitraclip, Amplatzer Amulet |
| Baxter Healthcare | $76.65 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
| Janssen Pharmaceuticals, INC | $71.75 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $32.41 | 2025 | Lifevest |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $26.73 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $26.12 | 2024 | Arcalyst |
| Edwards Lifesciences Corporation | $21.94 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Portola Pharmaceuticals, LLC | $12.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Silpa Avula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.